Chlorhexidine + Ketoconazole + Phytosphingosine

Verify with FDA CVM →

30 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
30
Total Reports
1
Deaths Reported
330.0%
Death Rate

Active Ingredients

ChlorhexidineChlorhexidine + Ketoconazole + PhytosphingosineKetoconazolePhytosphingosine

Administration Routes

TopicalAuricular (Otic)UnknownCutaneous

Species Affected

Dog 28
Human 1
Cat 1

Most Affected Breeds

Crossbred Canine/dog 3
Havanese 2
Terrier - Jack Russell 2
Pug 2
Spaniel - Cocker American 2
Retriever - Labrador 2
Chihuahua 1
Dachshund - Miniature 1
Shih Tzu 1
Schnauzer - Miniature 1

Most Reported Reactions

Vomiting 4
Pruritus 4
Lack of efficacy - NOS 4
Emesis 3
Pustules 3
Application site erythema 3
Skin irritation 3
Ear discharge 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Not eating 2
Localised pain NOS (see other 'SOCs' for specific pain) 2
Behavioural disorder NOS 2

Outcome Breakdown

Outcome Unknown
11 (36.7%)
Recovered/Normal
11 (36.7%)
Ongoing
6 (20.0%)
Died
1 (3.3%)
Recovered with Sequela
1 (3.3%)

Data Summary

Metric Value
Total adverse event reports 30
Reports involving death 1
Case-fatality rate (reported events) 330.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 4

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Chlorhexidine + Ketoconazole + Phytosphingosine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 30 adverse event reports referencing Chlorhexidine + Ketoconazole + Phytosphingosine, including 1 reports in which the animal died — a 330.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Chlorhexidine, Chlorhexidine + Ketoconazole + Phytosphingosine, Ketoconazole, Phytosphingosine. Reported administration routes include Topical, Auricular (Otic), Unknown, Cutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Chlorhexidine + Ketoconazole + Phytosphingosine reports are Dog (28 reports), Human (1 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (3), Havanese (2), Terrier - Jack Russell (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Chlorhexidine + Ketoconazole + Phytosphingosine are Vomiting (4), Pruritus (4), Lack of efficacy - NOS (4), Emesis (3). Of the 30 reports with a coded outcome, Outcome Unknown is the leading category at 36.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Chlorhexidine + Ketoconazole + Phytosphingosine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial